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ABSTRACT  
Azathioprine, a purine antimetabolite immunosuppressant, photosensitises the skin 
and causes the production of mutagenic reactive oxygen species.  It is postulated to increase 
the risk of squamous cell carcinoma (SCC) and other skin cancers in organ transplant 
recipients (OTRs), but evidence from multiple, largely single-centre studies to date has been 
inconsistent. We aimed to resolve the issue of azathioprine’s carcinogenicity by conducting a 
systematic review of the relevant literature and pooling published risk estimates to evaluate 
the risks of SCC, basal cell carcinoma (BCC), keratinocyte cancers (KC) overall, and other 
skin cancers, in relation to azathioprine treatment. 27 studies were included in total, with risk 
estimates from 13 of these studies able to be pooled for quantitative analysis.  The overall 
summary estimate showed a significantly increased risk of SCC in relation to azathioprine 
exposure (1.56, 95% confidence interval, CI, 1.11-2.18). No significant associations between 
azathioprine treatment and BCC (0.96, 95% CI 0.66-1.40) or KC (0.84, 95% CI 0.59-1.21) 
risk were observed. There was significant heterogeneity between studies for azathioprine risk 
estimates and the outcomes of SCC, BCC and KC. The pooled findings of available evidence 
support the contention that treatment with azathioprine increases the risk of SCC in OTRs. 
 
INTRODUCTION  
Solid organ transplant recipients (OTRs) are at an increased risk of developing skin 
cancer, particularly cutaneous squamous cell carcinoma (SCC) (1, 2). When compared with 
the general population, OTRs are 65-250 times more likely to develop SCC (3, 4). Other skin 
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malignancies including basal cell carcinoma (BCC), melanoma and Merkel cell carcinoma 
(MCC) have also been reported with increasing frequency (4-7). As the most common 
malignancy post-transplantation, skin cancer represents a major cause of morbidity and 
mortality in this population (8, 9).  
Immunosuppressive agents are contributing factors to skin carcinogenesis because 
they impair DNA repair mechanisms, reduce immunological clearance of malignant cells and 
upregulate cytokines that promote tumour progression (10-13). Azathioprine, a purine 
antimetabolite immunosuppressant, is thought to additionally heighten SCC risk via 
photosensitisation (14, 15) and an accumulation of 6-thioguanine in DNA, which causes the 
production of mutagenic reactive oxygen species when exposed to ultraviolet-A (UVA) (16).   
There have been significant changes in maintenance immunosuppression over recent 
decades. Azathioprine was the main agent used in the early years of transplantation and 
continued to be an integral part of the immunosuppressant regimen until the introduction of 
mycophenolic acid (MPA) in the late 1990’s. However, many long-term survivors with stable 
graft function remain on azathioprine, with a recent USA study reporting approximately 9% 
of kidney transplant recipients using this agent (17). In the Australian renal transplant 
population, 5-7% of patients transplanted between 2006 – 2010 were on azathioprine at two 
years post-transplantation (18).  In addition, azathioprine is used in patients who are 
intolerant of MPA, particularly its gastro-intestinal side-effects. Moreover MPA is 
contraindicated in women contemplating pregnancy and there has been recent upgrading of 
this advice by the European Medicines Agency to include avoidance of MPA by male 
transplant recipients whose female partner is planning a pregnancy (19).  Azathioprine 
remains widely used after cardiothoracic transplantation, with a Spanish study reporting 
prevalence of azathioprine use as high as 69% in heart transplant recipients (20).   
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It is speculated that azathioprine confers a greater risk of skin cancer, particularly 
keratinocyte cancer (KC), than other immunosuppressants, but results of studies to date have 
been conflicting (20, 21). A meta-analysis of patients with inflammatory bowel disease found 
an increased risk of KCs in patients treated with azathioprine when compared with healthy 
controls, or controls with inflammatory bowel disease but no azathioprine exposure (22). 
However, no systematic review of the risk of skin cancer in OTRs on azathioprine treatment 
in comparison with other immunosuppressive agents has been conducted. The question of 
possible carcinogenicity of azathioprine remains a very pertinent clinical question as the 
answer can provide new guidance on appropriate selection of immunosuppressant 
medication. We therefore systematically reviewed all relevant published studies and have 
summarised the evidence with pooled risk estimates, aiming to resolve the question of 
whether skin cancer risk is increased after azathioprine treatment.   
 
METHODS 
Search strategy 
A systematic literature search of Medline (PubMed and Ovid) EMBASE, CINAHL 
and The Cochrane Library was conducted using the following search terms: “azathioprine”,  
“6 thiopurine”,  “thiopurine”, “immunosuppressant*”, “immunosuppressive agent*”, “skin 
cancer”, “skin neoplas*”, “squamous cell cancer”, “squamous cell carcinoma”, “basal cell 
cancer”, “basal cell carcinoma”, “SCC”, “BCC”, “non melanoma skin cancer”, 
“nonmelanoma skin cancer”, “NMSC”, “melanoma”, “malignant melanoma” and 
“transplant*”. A full list of search strategies for the different databases is reported in the 
Supplemental Methods in the Supporting Information. All relevant studies were identified by 
a single reviewer. Titles and abstracts were initially checked and studies which combined 
internal malignancies with skin cancer as an outcome were excluded, as were review articles 
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and laboratory-based studies. The full-texts of identified studies were then reviewed and 
those which met the inclusion criteria were used to perform reference hand-searching and 
citation searching using the Web of Science.  All excluded studies were recorded with 
reasons for exclusion (Table S1).  
 
Inclusion criteria  
Studies were eligible for inclusion if they examined the risk of developing skin cancer 
in OTRs in relation to azathioprine treatment.  Studies which reported azathioprine use in any 
treatment combination were considered but they were excluded if there was no clear 
definition of the immunosuppressive regimens or if all comparison groups contained 
azathioprine.  Studies that only analysed dosage of immunosuppressants were also excluded 
as the lack of uniformity in dosage assessment prevented comparisons between studies. 
Comparisons between azathioprine and cyclosporine, MPA or tacrolimus were recorded but 
mTOR inhibitors and corticosteroids were excluded as corticosteroid use is generally 
universal and mTOR inhibitors may inhibit skin cancer formation (23, 24). Whilst our 
primary outcome of interest was SCC risk, risk of other types of skin cancer was a secondary 
outcome and we therefore also included studies reporting these risks. Studies published only 
as abstracts were excluded. If a series of publications covered the same study population, 
only the most comprehensive study was included. For inclusion in the meta-analysis, it was 
necessary that studies reported odds ratio (OR), relative risk (RR) or hazard ratio (HR) 
estimates with 95% confidence intervals (CI). Studies that did not include this information 
were summarised narratively.  
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Data extraction and quality assessment 
Data from included studies were extracted according to a pre-defined protocol 
(Supplemental Methods) and recorded in a data extraction table. Reporting was conducted in 
accordance with PRISMA guidelines (25).  Data extracted included author and publication 
year, study location and study design, population size and sex distribution, graft type, period 
of transplantation, duration and type of immunosuppression, and follow-up time. The type of 
skin cancer assessed in relation to azathioprine exposure was also recorded and subsequently 
categorised into one of four groups: a) ‘SCC’ for studies which reviewed SCC risk as an 
outcome, b) ‘BCC’ for the outcome of BCC risk, c) ‘KC’ for studies that combined SCC and 
BCC risk together, with the addition of SCC in-situ in some studies, d) ‘other skin cancer’ for 
studies that analysed the risk of melanoma, MCC, Kaposi’s sarcoma (KS), B-cell lymphoma, 
lip cancer or other rare skin cancers - alone or in combination with KCs. For studies where 
risk estimates for azathioprine were available, additional information was extracted including 
numbers of cases and controls, adjusted risk estimates with 95% confidence intervals (CIs) 
and adjusted factors or matched variables.  Disagreements and uncertainties were discussed 
and resolved by consensus agreement between investigators.  
The quality of studies was assessed using a scoring system based on the following 
guidelines: MOOSE – Meta-analysis Of Observational Studies in Epidemiology  (26), 
STROBE – Strengthening the Reporting of Observational studies in Epidemiology, (27), 
QATSO – Quality Assessment Tool for Systematic reviews of Observational studies (28) and 
Newcastle-Ottawa Scale (29). The evaluation was based on four key aspects: study design, 
consideration of confounding factors, exposure definition and outcome assessment. For study 
design, cohort studies and randomised trials were allocated two points, population-based 
case-control studies one point and clinic-based case-control studies 0 points. A maximum of 
two points were allocated for assessment of confounding: one point for age and sex 
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adjustment or matching and one point for adjusting /matching for other significant factors, 
namely duration of immunosuppression, graft organ and donor type. A single point was 
awarded if studies included an adequate definition of azathioprine exposure. With regards to 
outcome reporting, two areas were reviewed with a maximum of three points available: 
firstly, two points were allocated for independent follow-up of skin cancer outcomes, one 
point if this was assessed via registry linkage, a local database or medical records and 0 
points for self-reporting or no description. Secondly, one point was allocated for studies 
which had an adequate follow-up time which was deemed to be an average of five years or 
more. Studies with a total score of 0-2 were considered low quality, 3-5 moderate quality and 
6-8 high quality.  
 
Statistical analysis 
A random effects meta-analysis model was used to calculate the pooled estimate and 
account for the heterogeneity between studies (30). Where studies had several risk estimates 
for azathioprine exposure, the different groups were included in the analysis if they were 
believed to be mutually exclusive. Cochran’s Q test was applied to test for statistical 
heterogeneity among the pooled estimates (31). We also calculated the I2 statistic to quantify 
the proportion of heterogeneity in individual studies (32).  This value ranges from 0 to 100% 
with values of 25, 50 and 75% representing low, moderate and high heterogeneity, 
respectively (33). To identify an excessive influence of one study, we performed sensitivity 
analyses by excluding individual studies one at a time and observing the influence on the 
pooled estimate.  Publication bias was assessed by visual inspection of funnel plots and the 
Begg and Egger tests (34, 35). Analyses were performed for each of the main skin cancer 
outcomes (SCC, BCC and KC) with relative risk (RR), odds ratios (OR) and hazard ratios 
(HR) pooled for the meta-analysis. Where studies reported estimates of regimens including 
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azathioprine or ever-use of azathioprine, the latter was preferentially chosen. If studies 
reported risk estimates adjusted for immunosuppression dosing, the unadjusted risk estimates 
were included in the meta-analysis because the focus of our study was individual drugs rather 
than immunosuppression dose.  
 
Subgroup analysis 
Further analysis was performed to identify significant differences between subgroups 
and examine the consistency of the association between azathioprine and skin cancer risk. 
Five pre-specified subgroups were analysed: study design (cohort vs. case-control), graft type 
(kidney vs. heart), immunosuppressive therapy (dual vs triple), outcome assessment 
(independently assessed vs. registry linkage/local database/medical records), sun exposure 
(high sun exposure: study conducted at low average latitude (340-200) vs. low sun exposure: 
study conducted at high/middle average latitude (>340)) and quality assessment (high vs. low-
medium). All statistical analyses were performed with the software STATA version 10.0 
(Stata corporation, College Station, TX, USA). 
 
RESULTS 
Study selection and study characteristics 
The systematic search identified a total of 568 articles (Figure 1). After 32 duplicates 
were removed, 536 records were screened by title and abstract. The full-texts of 55 articles 
were assessed for eligibility and 28 were excluded for the following reasons (Table S1): skin 
cancer outcomes not reported separately (eight studies), exposure categories not clearly 
defined (two studies), azathioprine not specifically assessed as a risk factor (eight studies), 
azathioprine used in all comparison groups (three studies), conference abstract only (one 
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article), relating to a larger published study (three articles) and other miscellaneous reasons 
(three studies; Table S1). 
Twenty-seven articles were included in the final analysis, 23 cohort studies, one 
randomised trial and three case-control studies. Thirteen of these studies reported sufficient 
quantitative data to enable inclusion in the meta-analysis.  
 
Quality assessment 
The majority of included studies were deemed to be high quality (5, 6, 21, 36-47). 
Ten were assessed as medium quality (2, 3, 17, 20, 48-53) and two were low quality (54, 55) 
(Table S2). 
 
SCC risk  
Eleven studies assessed the relationship between azathioprine exposure and SCC in 
OTRs  (3, 17, 20, 21, 36, 40, 41, 47, 48, 50, 54) (Table 1) and 10 of the 11 were eligible for 
inclusion in the meta-analysis (50) (Table S3).  Two studies were population-based case-
control studies (17, 48) whilst the remainder were cohort studies. Four studies showed a 
significant association between azathioprine use and SCC risk (17, 20, 47, 48) with the rest 
reporting no significant association.  
In one study, only participants on triple therapy with cyclosporine, azathioprine and 
prednisolone had an increased risk of SCC (47). Similarly, another study showed that triple 
therapy with cyclosporine, azathioprine and prednisolone was associated with a significantly 
increased risk of SCC when compared with dual therapy with either azathioprine and 
prednisolone or cyclosporine and prednisolone (3).  
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The single study excluded from the quantitative analysis found no association 
between different immunosuppression regimens and SCC risk (risk estimates not reported) 
(50). 
The overall summary estimate for SCC risk in relation to azathioprine treatment in 
any combination was 1.56 (95% CI 1.11-2.18) with significant heterogeneity (P <0.001; 
Figure 2) (Table 2).  Estimates from all studies ranged from 0.64 to 8.64. The pooled effect 
estimate was significantly higher when restricting to case-control studies (n= 2) (7.04, 95% 
CI 3.82-12.94) whilst it was not significant in the assessment of cohort studies alone (n= 8) 
(1.24, 95% CI 0.99-1.54). Additionally, subgroup analysis of organ type (kidney vs. heart) 
showed a significant association with azathioprine exposure in the kidney transplant 
recipients studies (n= 4) (1.29, 95% CI 1.00-1.68) but not in heart transplant recipients (n= 2) 
(1.33, 95% CI 0.70-2.53). Triple drug therapy with azathioprine was associated with a 
significantly increased risk of SCC when compared with dual azathioprine 
immunosuppression therapy (2.38, 95% CI 1.23-4.63). The pooled risk estimate was higher 
in studies which directly followed-up SCC outcomes after treatment than in those that relied 
on registry linkage/local database/medical records (2.01 vs. 1.60, respectively), however, 
there was significant heterogeneity in the analysis of the latter group (P < 0.001). Eight 
studies based in countries with low sun exposure had a pooled risk estimate of 1.86 (95% CI 
1.04-3.33) while the risk estimate from two studies in countries with high sun exposure was 
not as elevated and fell short of statistical significance (1.25, 95% CI 0.95-1.64) (Table 2). 
The pooled estimate did not differ according to the quality of studies.  There was no evidence 
of publication bias (P-values for Begg 0.392 and Egger 0.366). 
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BCC risk 
Six cohort studies evaluated the risk of BCC in relation to azathioprine exposure and 
all were included in the quantitative analysis (20, 21, 36, 40, 47, 54). Three studies reported a 
significant association with azathioprine exposure with one study showing an increased risk 
of BCC (21) and two showing a protective effect of azathioprine treatment (36, 47).  The 
overall summary estimate for all studies was 0.96 (95% CI 0.66-1.40; Figure 3) and risk 
estimates ranged from 0.20 to 2.10 with significant heterogeneity (P = 0.001).  The pooled 
effect estimate did not differ according to organ type, immunosuppressive therapy, method of 
outcome assessment, sun exposure or quality assessment. There was no evidence of 
publication bias (P-values for Begg 0.087 and Egger 0.213). 
 
KC risk 
Of the eight studies that examined the risk of KC (combined risk of SCC and BCC) in 
relation to azathioprine exposure, seven were cohort studies (2, 21, 37-39, 44, 51) and one 
was a randomised trial (43).  Three studies included SCC in-situ (39, 44, 51) and the 
remaining five evaluated BCC and SCC alone (2, 21, 37, 38, 43). A significant association 
between azathioprine exposure and overall KC risk was not seen in any of the studies.  
Four studies which reported combined BCC and SCC risk estimates were included in 
the quantitative analysis (21, 37-39). The summary risk estimate was 0.84 (95% CI, 0.59-
1.21; Figure 4) and across all studies the estimates ranged from 0.59 to 1.40 with borderline 
significant heterogeneity (P = 0.048).  There were only four relevant studies from countries 
where sun exposure could be inferred and the smaller summary risk estimate from the low 
sun exposure countries had wide confidence limits (0.48, 95% CI 0.24-0.94), compared with 
the risk based on a single study in a high sun exposure population (1.12, 95% CI 0.85-1.48) 
(Table 2).  The pooled estimate did not differ according to immunosuppressive therapy 
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regimen or method of outcome assessment. There was evidence of significant publication 
bias (P-values for Begg 0.016 and Egger 0.001). 
 
Risk of other skin cancers  
Ten cohort studies and one clinic-based case-control study reported on the association 
between azathioprine risk and various other skin cancers.  The risk of melanoma was 
evaluated in six studies (5, 45, 46, 52, 54, 55), MCC in three (6, 52, 54), KS in five (20, 46, 
49, 52, 53) and other rare skin cancers (e.g. atypical fibroxanthoma, B-cell lymphoma) in 
four studies (20, 45, 52, 54). All but three studies combined multiple types of skin cancers (5, 
6, 42) and seven studies combined KCs with other skin cancers (20, 45, 46, 49, 52, 53, 55). 
Azathioprine exposure was associated with a significantly increased risk of melanoma (5), 
MCC (6), lip cancer (42), KS in combination with KCs (49), KS combined with KCs and 
other rare cancers (e.g. undifferentiated malignant tumours, neuroectodermal cancers) (20) 
and KS in combination with KCs and actinic keratosis (55). All other studies reported no 
significant associations with azathioprine exposure.  
Six studies reported risk estimates, however the results were not pooled as the skin 
cancer outcomes varied considerably in these studies (5, 6, 20, 42, 49, 54). 
 
DISCUSSION 
We found the risk of SCC in OTRs treated with azathioprine was significantly 
increased by 56% compared to SCC risk in those not treated with azathioprine but with other 
immunosuppressant drugs. However, there was pronounced heterogeneity between studies, 
likely due to differences in study design, organ type and period of transplantation.  Despite 
the substantial heterogeneity which would tend to dilute the observed summary risk estimate, 
a significant effect of azathioprine was detected. Thus we consider our summary estimate 
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may be a conservative estimate of the risk associated with azathioprine. When grouped by 
study design, population-based case-control studies showed a much greater pooled risk 
estimate than cohort studies. This is possibly due to the variation in exposure definition (both 
case-control studies in the meta-analysis defined azathioprine exposure as never-ever, 
compared with cohort studies that mainly assessed specific regimen combinations containing 
azathioprine, or reported on recent immunosuppressant use without regard to prior exposure). 
The pooled estimate for SCC risk was higher in countries with low sun exposure compared to 
those with high sun exposure. This may be because both case-control studies were based in 
low sun exposure countries and it may also be that the association with azathioprine is 
masked in the presence of the dominant effect of high sun exposure.  
This result is supported by studies which have highlighted the potential carcinogenic 
mechanism of azathioprine. Firstly, it has been shown that azathioprine sensitises the skin to 
UVA radiation and causes the accumulation of 6-thioguanine in DNA (14, 16). A further 
study examining the effect of biologically relevant doses of UVA in cells cultured with 6-
thioguanine show that 6-thioguanine and UVA are synergistically mutagenic, generating high 
levels of reactive oxygen species which may increase the risk of SCC (16). 
No significant association was found between azathioprine treatment and BCC or KC 
risk.  It is likely that KC combines heterogeneous skin cancers outcomes if azathioprine 
affects SCC vs BCC risk differentially.  It is also possible that because the incidence of BCC 
increases linearly following transplantation whereas SCC rises exponentially, a greater 
number of studies with a lengthy follow-up period are required to accurately assess the 
influence of azathioprine on BCC risk (56).   
Tailoring immunosuppressive regimens post-transplantation is important for 
controlling undesirable effects in patients at increased risk of specific conditions or under 
circumstances such as family planning. Risk factors for developing SCC after organ 
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transplant include older age at transplantation, fair skin type, high sun exposure, frequent 
sunburns in childhood, a history of skin cancer pre-transplantation and rejection episodes in 
the first year of transplantation (47, 57, 58). Therefore, the avoidance of azathioprine in 
OTRs with one or more of these risk factors may help reduce the future risk of SCC.  
 
Strength and limitations 
This study is novel in systematically summarising all available data on azathioprine 
use and skin cancer risk in OTRs and providing a pooled risk estimate separately for SCC and 
BCC, with detailed assessment of the methodological quality of included studies.  However, 
the definition of azathioprine exposure varied considerably between studies ranging from 
ever exposure, to use at baseline, use at one year post-transplant whilst in many studies it was 
undefined. Additionally, some studies examined azathioprine use with any combination of 
immunosuppressants, others outlined specific regimens and several studies did not provide 
any treatment detail despite the demonstrated importance of treatment combinations (3, 59, 
60). In fact, only nine of the 13 studies included in the meta-analysis provided an adequate 
definition by which to assess azathioprine exposure.  We did not limit the study to a single 
organ type to ensure a more comprehensive review.  However, doses of immunosuppressant 
medication vary widely between graft organs and some studies have suggested it is dosage, 
rather than individual drugs, that is a significant risk factor for skin cancer (3, 58, 61, 62). 
Dosage of immunosuppression could not be collectively and fully assessed as most studies 
did not analyse this or did not do so in a reproducible, straightforward manner (e.g. they used 
their own weighted formulae).  It is not uncommon for OTRs to undergo changes in their 
maintenance immunosuppression and this poses a further challenge when attempting to 
analyse the effects of a single agent. Additionally, referent immunosuppression groups were 
not consistent amongst studies with variations ranging from no exposure to azathioprine, 
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cyclosporine alone, cyclosporine and prednisolone, cyclosporine with MPA and prednisolone 
and in some studies this was undefined.  
Outcome definitions were also variable. Studies that defined the outcome as ‘skin 
cancer’ included KCs as well as actinic keratosis, KS, melanoma, MCC, B-cell lymphoma, 
vulval intraepithelial neoplasia and atypical fibroxanthoma. One study that defined the 
outcome as ‘nonmelanoma skin cancer’ also included KS, undifferentiated tumours and 
adenocarcinomas and therefore this was analysed under the outcome category ‘other skin 
cancer’.  We analysed the outcome of KC because many studies did not separate BCC and 
SCC, but grouped these together as nonmelanoma skin cancer. However, we believe that 
azathioprine may not have a similar effect on both cancers and we recommend that future 
studies avoid combining risks.  Moreover, it was for this reason that we only examined KC 
risk if studies had combined SCC and BCC, rather than amalgamating all studies under this 
heading.  
Several studies based the outcome assessment on registry data which has significant 
limitations with regards to skin cancer reporting (1, 63). This may partly explain the result of 
the subgroup analysis of studies that directly assessed SCC which showed a significantly 
higher pooled estimate than those that used other less rigorous methods of assessing the 
outcome. 
The year of transplantation ranged from 1963-2011 in the included studies and most 
reported sole use of azathioprine prior to 1983, after which cyclosporine came into general 
use.   These period differences can affect skin cancer rates due to changes in induction 
protocols over time, increased awareness and improved detection of skin cancer and 
increasing survival of OTRs, which some attribute to the introduction of cyclosporine (64-
68).  Subgroup analysis was not conducted for transplant period as there was significant 
overlap between time periods within studies and meaningful analysis was not possible.  
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In summary, based on current published data, we found an increased risk of SCC in 
OTRs treated with azathioprine, although considerable variations in measurement of 
azathioprine exposure and skin cancer outcomes existed between studies. Further high-
quality studies are required using standard categorisation to quantify azathioprine exposure 
and facilitate study comparisons. We also strongly recommend that future studies examine 
SCC and BCC risk separately, as there appears to be a differential risk post-transplantation in 
response to azathioprine treatment. 
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Figure Legends 
 
Figure 1: Flow diagram of study selection and search strategy 
Figure 2: Forest plot of the association between azathioprine exposure and squamous 
cell carcinoma 
Figure 3: Forest plot of the association between azathioprine exposure and basal cell 
carcinoma 
Figure 4: Forest plot of the association between azathioprine exposure and keratinocyte 
cancer 
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Additional Supporting Information may be found in the online version of this article. 
Supplemental Material 
Table S1. Summary of excluded studies with reasons for exclusion  
Table S2. Quality assessment of 27 included sites 
Table S3. Summary of 13 studies included in the meta-analysis, with reported risk 
estimates in relation to azathioprine exposure 
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years 
(mea
n 4.5 
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2006 
A Mean 
6 
years 
Other 
SC 
 
Savoia 
2011 
Italy Cohort 282 
 
61
% 
Median 
50 
years  
K 1974-
2009 
Antimetabolit
e category 
Medi
an 
7.9 
years 
Other 
SC 
Einolla
hi 
2010 
Iran Cohort 11’255 
 
63
% 
With 
cancer: 
mean 
47 
years.  
Withou
t 
cancer: 
mean 
38 
years. 
K NS A NS Other 
SC 
 
Serdar 
2010 
Turkey Cohort 163 
 
60
% 
NS K 1989-
2009 
CAP 
TAP 
Mean 
5.6 
years 
Other 
SC 
Terhors
t 
2009 
German
y 
Case-
control 
139 69
% 
Cases: 
mean 
50 
years  
Control
s: mean 
53 
years  
K 
H 
Li 
Lu  
K-P 
 
NS A NS Other 
SC 
van 
Leeuwe
n 
2009  
 
Australi
a 
Cohort 8162 59
% 
Median 
43 
years 
K 1982-
2003 
A 
 
Time-
dependent 
variable to 
represent 
current 
receipt at 
different 
intervals 
NS Other 
SC 
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1K: kidney; H: heart; Li: liver; Lu: lung; P: pancreas. 
2A: azathioprine; C: cyclosporine; P: prednisolone; T: tacrolimus. 
3Outcome categories: SCC, BCC, KC (SCC + BCC +/- SCC in-situ), other skin cancer, SC 
(any of the following alone or combined with KCs: actinic keratosis, MM, MCC, KS, B cell 
lymphoma, vulval intraepithelial neoplasia, cancer of lower vermillion lip, other rare 
cancers). 
4NS: not stated. 
5Of those with cancer. 
6Organ types not stated.  
 
BCC, basal cell carcinoma; KC, keratinocyte cancer; KS, Kaposi’s sarcoma; MCC, Merkel 
cell carcinoma; SCC, squamous cell carcinoma. 
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Table 2. Meta-analysis results using a random effects model: association of squamous cell carcinoma (SCC), basal cell carcinoma (BCC) 
and keratinocyte cancer (KC) with azathioprine treatment 
 SCC BCC KC 
Studies Risk estimate 
(95% CI) 
I
2 
(%) 
P het Studies Risk estimate 
(95% CI) 
I
2 
(%) 
P het Studies Risk estimate 
(95% CI) 
I
2 
(%) 
P het 
All studies 10 1.56 (1.11-2.18) 67.1 <0.001 6 0.96 (0.66-1.40) 65.7 0.001 4 0.84 (0.59-1.21) 52.8 0.048 
Study Design 
   Case-control 
    
   Cohort 
 
2 
 
8 
 
7.04 (3.82-12.94) 
 
1.24 (0.99-1.54) 
 
0.0 
 
21.7 
 
0.423 
 
0.218 
 
0 
 
6 
 
NA 
 
- 
 
- 
 
0 
 
4 
 
NA 
 
- 
 
- 
Organ type 
   Kidney 
    
   Heart 
 
4 
 
2 
 
1.29 (1.00-1.68) 
 
1.33 (0.70-2.53) 
 
0.0 
 
72.8 
 
0.642 
 
0.055 
 
3 
 
2 
 
0.94 (0.57-1.55) 
 
0.92 (0.34-2.45) 
 
68.5 
 
85.4 
 
0.002 
 
0.009 
 
3 
 
0 
 
NA 
 
- 
 
- 
Immunosuppressive therapy 
   Dual 
    
   Triple 
 
4 
 
2 
 
1.14 (0.75-1.73) 
 
2.38 (1.23-4.63) 
 
0.0 
 
0.0 
 
0.700 
 
0.836 
 
3 
 
1 
 
0.52 (0.14-1.94) 
 
1.00 (0.50-2.00) 
 
86.2 
 
- 
 
0.001 
 
- 
 
1 
 
1 
 
1.10 (0.68-1.80) 
 
0.67 (0.32-1.40) 
 
- 
 
- 
 
- 
 
- 
Outcome assessment 
    Independently assessed 
     
    Registry linkage/local      
    database/medical records 
 
3 
 
6 
 
2.01 (1.22-3.33) 
 
1.60 (1.04-2.46) 
 
0.0 
 
75.0 
 
0.913 
 
<0.001 
 
2 
 
3 
 
0.58 (0.26-1.31) 
 
1.23 (0.82-1.85) 
 
71.9 
 
75.5 
 
0.014 
 
0.038 
 
2 
 
2 
 
0.37 (0.10-1.40) 
 
1.04 (0.80-1.34) 
 
71.1 
 
0.6 
 
0.063 
 
0.403 
Sun exposure 
    High sun exposure 
     
    Low sun exposure 
 
2 
 
8 
 
1.25 (0.95-1.64) 
 
1.86 (1.04-3.33) 
 
0.0 
 
79.2 
 
0.526 
 
<0.001 
 
2 
 
4 
 
0.90 (0.51-1.58) 
 
1.03 (0.60-1.74) 
 
 
72.8 
 
58.0 
 
 
0.001 
 
0.067 
 
 
1 
 
3 
 
 
1.12 (0.85-1.48) 
 
0.48 (0.24-0.94) 
 
0.0 
 
45.6 
 
0.690 
 
0.159 
Quality assessment 
   High 
    
   Low-Medium 
 
5 
 
5 
 
1.21 (0.96-1.54) 
 
2.08 (0.94-4.61) 
 
0.0 
 
85.0 
 
0.616 
 
<0.001 
 
4 
 
2 
 
0.88 (0.56-1.39) 
1.42 (0.92-2.19) 
 
69.5 
 
0.0 
 
0.001 
 
0.625 
 
4 
 
0 
 
NA 
 
- 
 
- 
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